Castle Biosciences Showcases Innovative GEP Testing for Skin Cancer at 2025 Dermatology Conference

Castle Biosciences Advances Skin Cancer Management with Innovative GEP Testing Presentations

Castle Biosciences, Inc., a company headquartered in Friendswood, Texas, prepares to showcase its groundbreaking dermatologic gene expression profile (GEP) tests at the upcoming 2025 Winter Clinical Dermatology Conference in Waikoloa Village, Hawaii, from February 14-19. The company's commitment to enhancing patient care in skin cancer management is highlighted by its extensive research portfolio and innovative testing solutions. Dr. Rebecca Critchley-Thorne, the vice president of research and development at Castle Biosciences, emphasizes the importance of these advancements, noting that they aim to refine patient management strategies and improve clinical outcomes for individuals affected by skin cancers.

Among the key presentations, the "DecisionDx®-Melanoma" poster, led by Dr. J. Michael Guenther, illustrates the effectiveness of the i31-SLNB test. This test identifies melanoma patients with less than a 5% risk of sentinel lymph node (SLN) positivity, significantly aiding clinicians in making informed decisions about patient management and treatment pathways. Furthermore, the "DecisionDx®-SCC" presentation, directed by Karina Brito, BS, uses a 40-gene expression profile test to pinpoint immunosuppressed patients with T1-T2a cutaneous squamous cell carcinoma at a higher risk of metastasis. This information is crucial for tailoring adjuvant radiation therapy, ultimately enhancing patient care.

Another notable presentation, "MyPath® Melanoma," led by Brooke H. Russell, Ph.D., focuses on improving access to prognostic GEP testing for invasive melanoma through RNA-based testing. This initiative aims to streamline the diagnostic process, making it easier for healthcare providers to access vital prognostic information. With over 50 peer-reviewed studies supporting the DecisionDx-Melanoma test and an analysis of more than 10,000 patient samples, Castle Biosciences demonstrates its dedication to advancing the understanding and treatment of skin cancers. Attendees at the conference can view these presentations in the Queen's Ballroom and engage with the Castle Biosciences team at their booth in the exhibit hall.

In addition to these presentations, Castle Biosciences’ participation in the Winter Clinical Dermatology Conference underscores its leadership in the dermatology sector, particularly in the field of personalized medicine for skin cancer. The company’s research initiatives not only contribute to improved patient outcomes but also further the dialogue on innovative testing methodologies within the industry. As the conference approaches, the anticipation builds around Castle Biosciences' contributions to the future of skin cancer treatment and management.